New Alzheimer’s drug approved in UK

New Alzheimer’s drug approved in UK, but government won’t pay for it
The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months. View on euronews
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.– What kind of treatment is Donanemab?
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the company said on Wednesday.
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its costs.
Donanemab: NHS rejects second promising drug for Alzheimer’s
A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
New Alzheimer’s drugs should be available on NHS, says patient’s wife
A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like him will be able to access treatments. New disease-modifying Alzheimer’s drugs work best when they are given to patients in the early stages of disease.
'Alzheimer's drugs will come too late for us'
A couple from Hull have called on the government to fund new Alzheimer's drugs, even though they say it will come "too late" to help them. Elaine Windass, whose husband, Brian, was diagnosed with Alzheimer's Disease in 2022,
Alzheimer’s wonder drug blocked on NHS over cost
The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for the disease safe for use but the rationing body has immediately ruled that it is too expensive for NHS patients.
Alzheimer's Society responds to approval of new Alzheimer's drug
The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare products Regulatory Agency (MHRA) announced on Wednesday, October 23, that it has approved the drug donanemab.
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.
BMJ18h
NICE rejects Alzheimer’s drug donanemab owing to cost and “significant health risks”
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the ...
Outsourcing-pharma17h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
WKBW2h
Researchers at UB working to create vaccine to treat Alzheimer's disease
There have been many promising leads for an Alzheimer's vaccine but new treatments have been slow to merge. Researchers at ...
National Institute for Health and Care Excellence23h
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...